Home » Stocks » Capricor Therapeutics

Capricor Therapeutics, Inc. (CAPR)

Stock Price: $6.18 USD 0.24 (4.04%)
Updated Aug 13, 2020 4:00 PM EDT - Market closed
Pre-market: $6.20 +0.02 (0.32%) Aug 14, 4:33 AM

Stock Price Chart

Key Info

Market Cap 121.89M
Revenue (ttm) 599,728
Net Income (ttm) -8.64M
Shares Out 19.72M
EPS (ttm) -1.15
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 13, 2020
Last Price $6.18
Previous Close $5.94
Change ($) 0.24
Change (%) 4.04%
Day's Open 5.87
Day's Range 5.82 - 6.23
Day's Volume 3,040,868
52-Week Range 0.88 - 12.32

More Stats

Market Cap 121.89M
Enterprise Value 85.96M
Earnings Date (est) Nov 5, 2020
Ex-Dividend Date n/a
Shares Outstanding 19.72M
Float 19.19M
EPS (basic) -1.26
EPS (diluted) -1.15
FCF / Share -0.45
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 442,735
Short Ratio 0.29
Short % of Float 6.17%
Beta 7.04
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 203.25
PB Ratio 9.71
Revenue 599,728
Operating Income -8.71M
Net Income -8.64M
Free Cash Flow -6.78M
Net Cash 35.93M
Net Cash / Share 1.82
Gross Margin -689.78%
Operating Margin -1,451.72%
Profit Margin -1,441.50%
FCF Margin -1,130.30%
ROA -39.74%
ROE -108.11%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (1)

Buy 1
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$12.00*
Low
12.0
Current: $6.18
High
12.0
Target: 12.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue1.011.672.674.005.524.790.501.901.35-
Revenue Growth-39.87%-37.32%-33.32%-27.53%15.27%851.19%-73.5%40.18%--
Gross Profit1.011.672.674.005.524.790.501.901.35-
Operating Income-7.73-15.33-12.86-16.98-12.61-6.02-6.90-2.10-4.90-6.29
Net Income-7.64-15.192.43-18.81-12.86-6.22-8.89-2.07-4.88-6.03
Shares Outstanding3.712.942.321.861.591.171.050.990.070.06
Earnings Per Share-2.06-5.170.90-10.10-8.10-5.30-8.50-2.10-65.00-95.00
Operating Cash Flow-6.82-13.86-14.23-14.45-10.820.96-6.14-2.06-4.65-4.32
Capital Expenditures--0.32-0.03-0.19-0.15-0.19-0.06-0.01--
Free Cash Flow-6.82-14.18-14.26-14.65-10.970.77-6.20-2.08-4.65-4.32
Cash & Equivalents9.897.5414.8717.5413.5711.013.464.381.093.38
Total Debt---13.919.169.163.96---
Net Cash / Debt9.897.5414.873.644.411.86-0.504.381.093.38
Assets11.119.2516.2718.7516.0713.635.545.421.373.67
Liabilities4.274.635.0522.7517.1019.886.070.530.541.07
Book Value6.844.6211.23-4.00-1.03-6.25-0.534.890.832.60
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Capricor Therapeutics, Inc.
Country United States
Employees 16
CEO Linda Marbán

Stock Information

Ticker Symbol CAPR
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: CAPR

Description

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy (DMD), and other rare disorders. The company's development stage drug candidates for cardiosphere-derived cells include CAP-1002, a cardiac cell derived therapy, which is in phase II clinical trial for the treatment of patients with late-stage DMD; and completed various trials investigating the use of CAP-1002 for the treatment of cardiac conditions, including heart failure and post myocardial infarction with cardiac dysfunction. It is also developing CAP-2003 that is in pre-clinical development for the treatment of inflammatory conditions. The company was founded in 2005 and is headquartered in Beverly Hills, California.